Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Phase 1/2
140
about 6.3 years
18–120
6 sites in CA, NC, NY +1
What this study is about
This trial is testing a treatment combination of Belzutifan and Zanzalintinib for people with kidney cancer that has returned after other treatments. The goal is to see if this combination is safe and effective in people who have clear cell renal cell carcinoma (ccRCC) and recurrent disease during or after anti-PD-(L)1 therapy.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Belzutifan
- 2.Take Zanzalintinib
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
belzutifan
oral (Oral Tablet)
Primary: Efficacy Phase: Number of participants who discontinue study treatment due to an AE, Efficacy Phase: Number of participants who experience one or more AEs, Efficacy Phase: Objective Response Rate (ORR), Safety Lead In Phase: Number of participants who discontinue study treatment due to an AE, Safety Lead In Phase: Number of participants who experience one or more adverse events (AEs)
Secondary: Efficacy Phase: Duration of response (DOR), Efficacy Phase: Overall survival (OS), Efficacy Phase: Progression-free survival (PFS)
Oncology